Deborah Jack, Chief Executive of NAT comments;

 “These vaccine trial results are very good news and represent a major breakthrough as it is the first time a vaccine candidate has shown real benefit in human trials. Ultimately vaccines are the most effective way by far of tackling serious infectious disease.  And with over 2 million new HIV infections a year this option is desperately needed.  Obviously there is much more work to do with these promising findings, but they justify the continuing investments and efforts of the international community, including the UK Government, to develop a vaccine.”

Notes to the editor:

Further information about the trial and press statements from the International AIDS Vaccine Initiative can be found at http://www.iavi.org/news-center/Pages/PressRelease.aspx?pubID=3158
 
For further information please contact:
Katherine Sladden
Communications Officer
NAT
020 7814 6733 press@nat.org.uk
 
NAT
NAT (National AIDS Trust) is the UK’s leading charity dedicated to transforming society’s response to HIV. We provide fresh thinking, expert advice and practical resources. We campaign for change.
Shaping attitudes. Challenging injustice. Changing lives.
 
www.nat.org.uk